Absci Corporation (ABSI) Research

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Market snapshot

Symbol
ABSI
Price
$7.41
Day change
+3.20%
Market cap
$1.2B
P/E ratio
-9.57x
52-week range
2.24-8.17
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.03

Peer companies

  • Corvus Pharmaceuticals, Inc. (CRVS)
  • Erasca, Inc. (ERAS)
  • Gossamer Bio, Inc. (GOSS)
  • MeiraGTx Holdings plc (MGTX)
  • MoonLake Immunotherapeutics (MLTX)
  • Olema Pharmaceuticals, Inc. (OLMA)
  • Prothena Corporation plc (PRTA)
  • REGENXBIO Inc. (RGNX)

Recent insider activity

  • Szela Mary T — A-Award (33200 shares) on 2026-06-04
  • Szela Mary T — A-Award (8400 shares) on 2026-06-04
  • MCGINNIS KAREN K — A-Award (10100 shares) on 2026-06-04
  • MCGINNIS KAREN K — A-Award (39800 shares) on 2026-06-04
  • Szela Mary T — A-Award (39800 shares) on 2026-06-04

Open Absci Corporation (ABSI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.